^
    2years
    (+)-JJ-74-138 is a novel non-competitive androgen receptor antagonist. (PubMed, Mol Cancer Ther)
    In addition, (+)-JJ-74-138 inhibited 22Rv1 xenograft tumor growth. Our observations suggest that (+)-JJ-74-138 is a novel non-competitive AR antagonist capable of inhibiting enzalutamide-resistant CRPC.
    Journal
    |
    AR (Androgen receptor) • KLK3 (Kallikrein-related peptidase 3)
    |
    AR expression • AR splice variant 7 • AR-V7 expression
    |
    Xtandi (enzalutamide capsule) • (+)-JJ-74-138